Comparative outcomes of thromboprophylaxis between low molecular weight heparin (LMWH) and rivaroxaban in surgical gastrointestinal cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190712003

Enrollment

760

Registered

2019-07-12

Start date

2019-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rivaroxaban &#44

Interventions

rivaroxaban 10 mg oral once daily,enoxaparin 0.4 ml sc once daily

Experimental Drug,Active Comparator Drug

rivaroxaban,enoxaparin

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: age > 18 years gastrointestinal cancer surgery

Exclusion criteria

Exclusion criteria: previous venous thromboembolism Preoperative DVT Coadministration of anticoagulant medication rivaroxaban drug allergy active clinical bleeding poor renal function (GFR < 30) impair liver function (Child-Pugh B and C) History of heparin induced thrombocytopenia

Design outcomes

Primary

Measure	Time frame
Venous thromboembolism 1 month Ultrasound	—

Secondary

Measure	Time frame
bleeding complication 1 month clinical diagnosis,cost-effectiveness 1 month cost of treatment,satisfaction scores 1 month record form	—

Countries

Thailand

Contacts

Public ContactSurakiat Bokerd

Vascular and transplant unit , department of surgery , ramathibodi hospital

big.bokerd@hotmail.com0880806249

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026